Literature DB >> 11918327

Value of sentinel node biopsy in the management of breast cancer.

R Manecksha1, A D Hill, B Dijkstra, L Kelly, C D Collins, E McDermott, N J O'Higgins.   

Abstract

AIMS: To determine the rate of detection of the sentinel node using both blue dye and radioisotope, and the accuracy with which the sentinel node histology reflects the nodal status of the axilla in a series of patients with clinically node-negative breast cancer. PATIENTS AND METHODS: During a 32-month period from May 1998 to December 2000, 73 patients with clinically node-negative breast cancer underwent sentinel node biopsy immediately followed by formal axillary lymphadenectomy. The sentinel node(s) was identified using a combination of lymphoscintigraphy, blue dye and an intraoperative hand-held gamma probe.
RESULTS: The mean age of the 73 patients was 58 years (range 32-83 years). Twenty-six per cent (19/73) had previous surgical/excisional biopsy. Pre-operative lymphoscintigraphy was positive in 74% (54/73) of patients. Combination of blue dye and radioisotope was better than either method in isolation for identifying the sentinel node, yielding a success rate of 96% (70/73). A total of 32 cases proved to have positive nodal disease on histological examination. In 44% (14/32) of patients, the sentinel node was the only positive node. Forty-seven per cent (15/32) of patients in whom the sentinel node was positive also had positive nodes in the axillary nodal basin. There were 3/32 false negative cases, giving a false negative rate of 9.4%.
CONCLUSION: Sentinel node biopsy will have a role in the management of breast cancer. However, widespread adaptation of this technique awaits the results of prospective, randomised trials.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11918327     DOI: 10.1007/BF03167785

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  18 in total

1.  Lessons learned from 500 cases of lymphatic mapping for breast cancer.

Authors:  A D Hill; K N Tran; T Akhurst; H Yeung; S D Yeh; P P Rosen; P I Borgen; H S Cody
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

2.  Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control.

Authors:  A Y de Kanter; A N van Geel; M A Paul; C H van Eijck; S C Henzen-Logmans; R H Kruyt; E P Krenning; A M Eggermont; T Wiggers
Journal:  Eur J Surg Oncol       Date:  2000-11       Impact factor: 4.424

3.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.

Authors:  P R Rosen; S Groshen; P E Saigo; D W Kinne; S Hellman
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

4.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.

Authors:  U Veronesi; G Paganelli; V Galimberti; G Viale; S Zurrida; M Bedoni; A Costa; C de Cicco; J G Geraghty; A Luini; V Sacchini; P Veronesi
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

5.  Dynamic lymphoscintigraphy to identify the sentinel and satellite nodes.

Authors:  A Taylor; D Murray; S Herda; J Vansant; N Alazraki
Journal:  Clin Nucl Med       Date:  1996-10       Impact factor: 7.794

Review 6.  Lymphoscintigraphy in oncology: a rediscovered challenge.

Authors:  R A Valdés Olmos; C A Hoefnagel; O E Nieweg; L Jansen; E J Rutgers; J Borger; S Horenblas; B B Kroon
Journal:  Eur J Nucl Med       Date:  1999-04

7.  Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center.

Authors:  B J O'Hea; A D Hill; A M El-Shirbiny; S D Yeh; P P Rosen; D G Coit; P I Borgen; H S Cody
Journal:  J Am Coll Surg       Date:  1998-04       Impact factor: 6.113

8.  Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye.

Authors:  L Tafra; D R Lannin; M S Swanson; K M Verbanac; A N Chua; P C Ng; M S Edwards; B E Halliday; C A Henry; L M Sommers; C M Carman; M R Molin; J E Yurko; R R Perry; R Williams
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

9.  Initial experience in a community hospital with sentinel lymph node mapping and biopsy for evaluation of axillary lymph node status in palpable invasive breast cancer.

Authors:  A Morgan; R L Howisey; H C Aldape; R G Patton; R K Rowbotham; E K Schmidt; C R Simrell
Journal:  J Surg Oncol       Date:  1999-09       Impact factor: 3.454

Review 10.  Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers.

Authors:  N P Alazraki; D Eshima; L A Eshima; S C Herda; D R Murray; J P Vansant; A T Taylor
Journal:  Semin Nucl Med       Date:  1997-01       Impact factor: 4.446

View more
  2 in total

1.  The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis.

Authors:  Sarah Pesek; Taka Ashikaga; Lars Erik Krag; David Krag
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

2.  Factors affecting metastases to non-sentinel lymph nodes in breast cancer.

Authors:  F J Fleming; D Kavanagh; T B Crotty; C M Quinn; E W McDermott; N O'Higgins; A D K Hill
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.